LB Pharmaceuticals Sets Oct. 27 R&D Day Ahead of Phase 3 Data
LB Pharmaceuticals will hold an in-person and virtual R&D Day on Oct. 27, spotlighting LB-102 ahead of a Phase 3 schizophrenia trial readout.
LB Pharmaceuticals Inc. (Nasdaq: LBRX) announced Tuesday it will host a combined in-person and virtual R&D Day on October 27, 2026, with presentations scheduled to begin at 2:00 PM ET, followed by a reception. The New York-based neuromedicines company said the event is timed ahead of its anticipated topline Phase 3 data readout for LB-102, its lead candidate targeting schizophrenia.
The program will feature University of Toronto psychiatrist Roger S. McIntyre, MD, FRCPC, a recognized researcher in brain disorders, alongside the company's full executive leadership team. CEO Heather Turner, Chief Medical Officer Susan G. Kozauer, Chief Commercial Officer Kaya Pai Panandiker, Chief Operating and Business Officer Gad Soffer, and CFO Joe Miller are all expected to present.
Read more Archer Lewis CEO Jake Nice Earns Crain's 40 Under 40 Honor →
LB Pharmaceuticals describes its mission as developing therapies that address multiple dimensions of underserved brain disorders. Schizophrenia, a condition affecting millions of Americans, remains an area of significant unmet medical need, with existing treatments often falling short on negative symptoms and cognitive deficits — dimensions the company has indicated LB-102 is designed to address.
The dual in-person and virtual format signals the company's intent to reach both institutional investors and a broader audience ahead of a data milestone that could prove pivotal for its pipeline and commercial trajectory. No financial guidance or updated clinical timelines were disclosed in connection with the event announcement.
Continue reading at GlobeNewswire - Industry News on Financial Services.
